National Institute of Child Health & Human Development looking for collaborators to work on immortalized virus-free human placental cell lines.
Virus-Free Human Placental Cell Lines To Study Genetic Functions
Background:
The National Institute of Child Health and Human Development’s Section on Cellular Differentiation is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize immortalized virus-free human placental cell lines.
Technology:
This technology describes immortalized virus-free human placental cell lines. To [...]
Good news received on companies for Week Ending June 19.
AEterna Zentaris Inc. of Quebec City, Canada, a global biopharmaceutical company focused on endocrine therapy and oncology, announced that they have received commitments to purchase US$10 million of units comprised of common shares and common share purchase warrants in a registered direct offering. AEterna Zentaris expects to receive net proceeds of approximately US$9.25 million after [...]
Twenty-nine new hot jobs for week ending June 22 including one COO, six Director level and 2 at the Vice President level.
Following are the 29 new positions we have picked up from various sources in the last week. If any of them are of interest, please feel free to call Bill Beattie at 413-788-2291 or email me at billb@ecibio.com
————————————————————————————————————————————————–
Biostatistician (SR) located in Michigan.
Must have masters Degree in Biostatistics and a minimum of three years experience.
Job # [...]
Merger between Merck and Schering-Plough. Does it make sense?
Now that the deal between Merck and Schering is well along, it is probably a good time to sit down and decide if it even made sense. Merck paid the proverbial kings ransom to buy Schering, a total of over $41 billion. Did they overpay? What is the rationale for even going through with the [...]
Companies receiving good news during week ending June 12.
Aileron Therapeutics, based in Cambridge, Massachusetts, has had 4 of the world’s biggest drugmakers invest in them. The venture arms of GlaxoSmithKline, Novartis, Roche and Eli Lilly are investing in a $40 million fundraising by Aileron.
It is believed that their synthetically locked, or “stapled”, peptides will be able to target biochemical pathways involved in cell [...]
BioTrove’s new RapidFire 300 system, announced recently at the ASMS show appears to be a winner.
We frequently write articles on this blog for new product introductions by the big dogs on the block, so it is always nice to write an article on an up and coming company. This is in fact the second article we have written on BioTrove. Back in the beginning of March, they had received an [...]
National Institute on Aging’s Lab of Cardiovascular Sciences is looking for collaborators interested in the study of mammalian membrane proteins.
Is it just me, or am I seeing a lot more requests for collaborations coming out of the NIH and affiliated organizations. Is this due to the money earmarked by the Obama administration to help the US economy?
Background:
The National Institute on Aging’s Laboratory of Cardiovascular Sciences is seeking statements of capability or interest from parties [...]
Companies receiving good news for week ending June 5, 2009
Concert Pharmaceuticals of Lexington, MA and Glaxo Smith Kline have announced they will collaborate to develop and commercialize deuterium-containing medicines. Total payments to Concert could reach $1 billion.
Under the terms of the agreement, Concert will receive $35 million in upfront payments, including a $16.7 million equity investment by GSK. Concert is also eligible to receive [...]
The NIH Laboratory of Proteomics and Analytical Technologies is looking for collaborators to help them develop cancer biomarkers from clinical specimens.
Renal Cancer Biomarkers
Background:
The National Cancer Institute’s Laboratory of Proteomics and Analytical Technologies is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize diagnostic, therapeutic and prognostic cancer biomarkers from clinical specimens.
Technology:
Renal Cell Carcinoma is the most common type of kidney cancer and its incidence is rising [...]
NIH’s Pediatric Oncology Branch seeking collaborators to work on genetically-modified T Cells as Cancer Immunotherapeutics.
Genetically-Modified T Cells As Cancer Immunotherapeutics
Background:
The National Cancer Institute’s Pediatric Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize genetically engineered lymphocytes with specificity for human survivin.
A major drawback of current chemotherapy-based cancer treatments is the harsh side-effects associated with many cancer drugs. [...]
Email delivery